Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
81%
Adult T-Cell Leukemia/Lymphoma
81%
Geriatric Assessment
67%
Progression Free Survival
64%
Human Immunodeficiency Virus
63%
Human T-Lymphotropic Virus 1
57%
Overall Survival
56%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
55%
Diseases
55%
Cutaneous Lymphoma
54%
Mycosis fungoides
54%
Sezary Syndrome
54%
Comorbidity
38%
Hodgkin's Lymphoma
37%
Oncology
37%
Dacarbazine
36%
Vinblastine
36%
Doxorubicin
36%
Bleomycin
36%
Human Immunodeficiency Virus Infection
35%
Prognostic Factor
35%
Neoplasm
33%
Polyethylene Terephthalate
32%
Malignant Neoplasm
30%
Highly Active Antiretroviral Therapy
30%
International Prognostic Index
29%
Rituximab
27%
Gemcitabine
27%
Oxaliplatin
27%
B Lymphocyte Receptor
27%
Classical Hodgkin Lymphoma
27%
Endobronchial Ultrasonography
27%
Cancer Treatment
27%
Elderly Patient
27%
Cancer Staging
27%
Fine-Needle Aspiration
27%
Positron Emission Tomography-Computed Tomography
27%
Survival Prediction
27%
Immunoglobulin Producing Cell
27%
Germinal Center
27%
Immunoglobulin A
27%
Aggressive Lymphoma
27%
Aciclovir
27%
Daclizumab
27%
Combination Therapy
27%
CHOP
27%
Lymphocyte
27%
Transbronchial Aspiration
24%
Disease Exacerbation
24%
Gut-Associated Lymphoid Tissue
23%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
T Cell Leukemia
81%
Overall Survival
74%
Rituximab
72%
Diffuse Large B Cell Lymphoma
54%
Gemcitabine
54%
Malignant Neoplasm
54%
HIV
54%
Cyclophosphamide
45%
Doxorubicin
45%
Vincristine
45%
Prednisolone
36%
Human T-Lymphotropic Virus 1
34%
Zidovudine
33%
Remission
31%
Diseases
30%
Combination Therapy
27%
COVID-19 Vaccine
27%
Immunogenicity
27%
Daclizumab
27%
Oxaliplatin
27%
Observational Study
27%
Classical Hodgkin Lymphoma
27%
Alpha Interferon
27%
Comorbidity
27%
Vinblastine
27%
Bleomycin
27%
Dacarbazine
27%
Progression Free Survival
23%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
18%
Anthracycline
16%
Febrile Neutropenia
13%
Infection
13%
Long Term Survival
11%
Event Free Survival
9%
Ifosfamide
9%
Cytarabine
9%
Treatment Group
9%
Etoposide
9%
Methotrexate
9%
Isoprenaline
6%
Hodgkin Disease
5%
Disease Free Survival
5%
Lymphocytosis
5%
Lactate Dehydrogenase
5%
Murine
5%
Skin Defect
5%
Basiliximab
5%
Hepatosplenomegaly
5%
Lymphadenopathy
5%
Immunology and Microbiology
B Cell
60%
Human immunodeficiency virus
54%
Severe Acute Respiratory Syndrome Coronavirus 2
45%
Progression Free Survival
45%
COVID-19
32%
Overall Survival
31%
B-Cell Receptor
27%
Immunoglobulin Producing Cell
27%
Cell Survival
27%
Immunogenicity
27%
Granulomatosis with Polyangiitis
27%
Germinal Center
27%
Survival Prediction
27%
Immunoglobulin A
27%
Survival Factor
27%
Autoantigen
27%
Positron Emission Tomography-Computed Tomography
27%
Metabolic Tumor Volume
27%
Gut-Associated Lymphoid Tissue
23%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Rituximab
18%
Cyclophosphamide
18%
Virus
16%
Seroconversion
13%
Quantitative Reverse Transcription Polymerase Chain Reaction
9%
Prednisolone
9%
Methotrexate
9%
Mucosa
8%
Immune Dysregulation
5%
Viral Shedding
5%
Cell Clone
5%
Immune System
5%
Prevalence
5%
T Cell
5%
Humoral Immunity
5%
